Hanumaiah Telikepalli

Materials Science · Physical Sciences

14h-index1.2kcitations41works0.52yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Crystallization and Solubility Studies(7), X-ray Diffraction in Crystallography(7), Microbial Natural Products and Biosynthesis(5), Lung Cancer Treatments and Mutations(5), Cancer Mechanisms and Therapy(5)

Publications41 total

Bioassay-directed Discovery of Natural Product Leads. Antibacterials and Antifungals From Unusual Sources
2026
Abstract 593: DCC-3084, a brain penetrant RAF dimer inhibitor, broadly inhibits BRAF class I, II, and III alterations leading to growth inhibition of intracranially implanted tumors in preclinical models
Cancer Research·2024· 1 cited
Abstract 4045: DCC-3084, a RAF dimer inhibitor, broadly inhibits BRAF class I, II, III, BRAF fusions, and RAS-driven solid tumors leading to tumor regression in preclinical models
Cancer Research·2023· 4 cited
Abstract 4033: Pan-exon mutant KIT inhibitor DCC-3009 demonstrates tumor regressions in preclinical gastrointestinal stromal tumor models
Cancer Research·2023
Supplementary Materials and Methods, Supplementary Tables 1 through 4, and Supplementary Figures 1 through 9 from Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2
2023Open Access
Data from Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2
2023Open Access
Data from Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2
2023Open Access
Supplementary Materials and Methods, Supplementary Tables 1 through 4, and Supplementary Figures 1 through 9 from Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2
2023Open Access
CCDC 2092504: Experimental Crystal Structure Determination
The Cambridge Structural Database·2021Open Access
CCDC 1974541: Experimental Crystal Structure Determination
The Cambridge Structural Database·2021Open Access
CCDC 1453984: Experimental Crystal Structure Determination
The Cambridge Structural Database·2021Open Access
Hydrophilic and hydrophobic carboxamide pincers as anion hosts
Organic & Biomolecular Chemistry·2021· 3 citedOpen Access
Abstract B129: Preclinical studies with DCC-3116, an ULK kinase inhibitor designed to inhibit autophagy as a potential strategy to address mutant RAS cancers
Molecular Cancer Therapeutics·2019· 6 cited
Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants
Cancer Cell·2019· 271 cited
Pyrazinetetracarboxamide: A Duplex Ligand for Palladium(II)
Inorganic Chemistry·2016· 12 cited
CCDC 1477195: Experimental Crystal Structure Determination
The Cambridge Structural Database·2016Open Access
CCDC 1453982: Experimental Crystal Structure Determination
The Cambridge Structural Database·2016Open Access
Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2
Molecular Cancer Therapeutics·2015· 75 cited
Discovery of 1-(3,3-Dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-<i>d</i>]pyrimidin-6-yl)phenyl)urea (LY3009120) as a Pan-RAF Inhibitor with Minimal Paradoxical Activation and Activity against <i>BRAF</i> or <i>RAS</i> Mutant Tumor Cells
Journal of Medicinal Chemistry·2015· 84 citedOpen Access
Conformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036
Cancer Cell·2011· 204 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Lester A. Mitscher(14), Bryan D. Smith(13), Daniel L. Flynn(12), Yu Mi Ahn(11), Molly M. Hood(11), Lakshminarayana Vogeti(11), Subha Vogeti(10), Michael D. Kaufman(9), Cynthia B. Leary(9), Scott Wise(9), Thomas J. Rutkoski(9), Timothy M. Caldwell(9), Lawrence Chun(9), William C. Patt(9), Carol L. Ensinger(8), Karen Yates(7), Jessica Lohrman(7), Victor W. Day(7), Kristin Bowman‐James(7), Benjamin A. Turner(6)